Skip to main content
OpenTrials
Completed

NCT Number: NCT01888107

Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

The purpose of this study is to assess the maintenance of antipsychotic efficacy and safety of risperidone long-acting injectable (RLAI) in patients with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) or schizoaffective (a mixed psychiatric disorder relating to a complex psychotic state that has features of both schizophrenia and a mood disorder such as bipolar disorder) disorder who were receiving treatment with any antipsychotic medication and who required a long-term antipsychotic therapy. The secondary aim is to investigate prospectively (a study that starts with the present condition of a population of individuals and follows them into the future) the prevalence of patients who met standardized remission criteria (according to Andreasen et al. criteria) and the psychopathological, psychosocial and subjective predictors of achieving remission.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Psychotic Disorders Schizoaffective Disorder Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

This is a prospective, open-label, (all people know the identity of the intervention), single-arm study conducted at 47 sites in Italy between January 2005 and April 2007. Approximately 338 patients with schizophrenia or schizoaffective disorder who were receiving treatment with any antipsychotic medication and who required a long-term antipsychotic therapy will be switched directly to RLAI without an oral risperidone run-in (the elapsed time before a trial is started when no treatment is given to patients in the study). They will be considered either not optimally treated or symptom-free. Patients will be either not hospitalized or living in residential structures at the time of the enrollment as well as throughout the study. The maximum duration of study participation will be 52 weeks. Patient safety will be monitored throughout the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
  • Required long-term antipsychotic therapy at the time of recruitment
  • Symptomatically stable and taking the same dose of antipsychotic agents for at least one month before the baseline visit (considered stable if there have been no appreciable change in symptoms over the previous month, regardless of the severity of their symptoms)
  • Patients or their legal representatives provided their written informed consent prior to enrollment in the study

Exclusion criteria

  • Patients who had received clozapine during the previous 3 months
  • Participated in an investigational drug trial in the previous 30 days
  • Previously been shown to be either intolerant or non-responsive to risperidone therapy
  • Presence of a serious unstable medical condition, such as a history or current symptoms of tardive dyskinesia or a history of neuroleptic malignant syndrome
  • Pregnant or breast-feeding; female patients of childbearing potential not using adequate contraception

Treatment and study plan

Risperidone Long-acting Injectable (LAI) 25 mg

Drug

Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.

Risperidone LAI 37.5 mg

Drug

Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.

Risperidone LAI 50 mg

Drug

Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.

Primary outcomes

  1. Change from Baseline in Positive and Negative Syndrome Scale (PANSS) total and subscales score

    Time frame: Baseline and after 4, 12, 26, 38 and 52 weeks

    Maintenance= Symptom severity assessed with PANSS scale vs baseline (Total, positive, negative, general psychopathology and cognitive cluster score); Remission= percentage of patients with 8 specific items PANSS simultaneously scoring <= 3 for at least 6 months

Secondary outcomes

  1. Clinical Global Impression-Severity (CGI-S) scale

    Time frame: Baseline

    This measure is used to evaluate disease severity at baseline (Visit 1).

  2. Change from Baseline in Clinical Global Impression-Change (CGI-C) scale

    Time frame: Baseline and after 4, 12, 26, 38 and 52 weeks

    This measure is used to evaluate disease severity at the other time points (Visits 2 to 6).

  3. Change from Baseline in Global Assessment of Functioning (GAF)

    Time frame: Baseline and after 4, 12, 26, 38 and 52 weeks

    GAF is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death. Lower scores indicate worsening.

  4. Change from Baseline in Drug Attitude Inventory (DAI 30)

    Time frame: Baseline and after 4, 12, 26, 38 and 52 weeks

    Personal attitude towards risperidone long-acting injectable treatment is rated by a subjective questionnaire that is administered at each study visit (1 through 6).

  5. The number of patients who experience adverse events as a measure of safety and tolerability.

    Time frame: Baseline and after 4, 12, 26, 38 and 52 weeks

Sponsors and collaborators

Lead sponsor

Janssen-Cilag S.p.A.

Industry

Registry information

Official study title

Maintenance of Clinical Response With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

Important dates

Study start
2005
Primary completion
2007
Study completion
2007
First posted
Jun 27, 2013
Registry last updated
Jun 27, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.